Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-04
2006-04-04
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S008100, C514S021800, C514S970000, C514S973000, C530S350000, C530S395000
Reexamination Certificate
active
07022672
ABSTRACT:
A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
REFERENCES:
patent: 4637834 (1987-01-01), Thurow
patent: 5051497 (1991-09-01), Fanning et al.
patent: 5212091 (1993-05-01), Diaz-Collier et al.
patent: 5276015 (1994-01-01), Khouri et al.
patent: 5276016 (1994-01-01), Khouri et al.
patent: 5358708 (1994-10-01), Patel
patent: 5466893 (1995-11-01), Nakatani
patent: 5503827 (1996-04-01), Woog et al.
patent: 6103500 (2000-08-01), Innis et al.
patent: 6323326 (2001-11-01), Dorin et al.
patent: 0 131 864 (1985-01-01), None
patent: 0 325 691 (1989-08-01), None
patent: 0473 564 (1992-03-01), None
patent: 0 559 632 (1993-09-01), None
patent: 0 559 832 (1993-09-01), None
patent: WO-93/25230 (1993-12-01), None
patent: WO 93/25230 (1993-12-01), None
Rainer Rudolph, “Successful Protein Folding on a Industrial Scale”, Protein Engineering: Principles and Practice, Chapter 10, pps. 283-298, dated 1998.
Rudolph & Lillie, “In vitro folding of Inclusion body proteins”, Folding of Acidic Fibroblast Growth Factor, FASEB J., 10, pps. 49-56, date unknown.
Dabora et al., “Effect of Polyanions on the Refolding of Human Acidic Fibroblast Growth Factor”, The Journal Of Biological Chemistry, vol. 266, No. 35, pps. 23637-23840, dated Dec. 15, 1991.
Bernhard Fisher et al., Isolation, Renaturation, and Formation of Disulflde Bonds of Eukaryotic Proteins Expressed inEscherichia colias Inclusion Bodies, Biotechnology and Bioengineering, vol. 41, pps. 3-13, dated 1993.
J. Harenberg, et al., Tissue factor pathway Inhibotor: proposed heparin recognition region, Blood Coagulation and Fibrinolysis, vol. 6, Supp. No. 1, pps. S50-S56, dated 1995.
Mark E. Gustafson et al., Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in RecombinantE. coli, Protein Expression and Purification, vol. 5, pps. 233-241, dated 1994.
Arve Bo H.
Bana Rejsharan K.
Bild Gary S.
Chen Bao-Lu
Dorin Glenn J.
Chiron Corporation
G. D. Searle, LLC
Harbin Alisa A.
Hemmendinger Lisa M.
Mitra Rita
LandOfFree
Formulation, solubilization, purification, and refolding of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation, solubilization, purification, and refolding of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation, solubilization, purification, and refolding of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544524